The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 03, 2015
Filed:
Apr. 28, 2006
Tetsuhiro Harakawa, Kumamoto, JP;
Hirotoshi Nakano, Kumamoto-ken, JP;
Yasushi Torii, Kumamoto, JP;
Sachio Okuda, Kumamoto, JP;
Ryuji Kaji, Tokushima, JP;
Takashi Sakamoto, Ichikawa, JP;
Motohide Takahashi, Musashimurayama, JP;
Setsuji Ishida, Narashino, JP;
Tetsuhiro Harakawa, Kumamoto, JP;
Hirotoshi Nakano, Kumamoto-ken, JP;
Yasushi Torii, Kumamoto, JP;
Sachio Okuda, Kumamoto, JP;
Ryuji Kaji, Tokushima, JP;
Takashi Sakamoto, Ichikawa, JP;
Motohide Takahashi, Musashimurayama, JP;
Setsuji Ishida, Narashino, JP;
Abstract
The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LDcurrently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.